ChiCTR1900022366
尚未开始
/
/
/
2019-04-08
/
/
非ST段抬高型心肌梗死
非ST段抬高型心肌梗死患者三甲胺氮氧化物与冠状动脉粥样硬化负荷的关系
非ST段抬高型心肌梗死患者三甲胺氮氧化物与冠状动脉粥样硬化负荷的关系
518055
Aims to evaluate the relationship between plasma TMAO levels, and the complexity and atherosclerotic burden in NSTEMI patients.
连续入组
其它
N/A
N/A
中国医学科学院阜外医院深圳医院
/
100
/
2019-04-15
2020-04-15
/
The present study will include two groups of individuals. The first group will include one hundred NSTEMI patients older than 18 years, those who will undergo emergency or primary coronary angiography or percutaneous coronary intervention (PCI) from 15th April 2019 to 15th April 2020. NSTEMI will define according to current ESC guideline as the presence of acute chest pain, but no persistent ST-segment elevation; electrocardiogram (ECG) change may include ST-segment depression ≥0.05 mV, T-wave inversion ≥0.3 mV or flat T wave, or transient ST-segment elevation ≤0.05 mV or may be normal ECG; and positive elevated troponin T or I and/or CK-MB exceeding the upper limit of normal range. The second group will include healthy individuals without known cardiovascular diseases those who will visit for health screen. The second group purpose will provide the reference interval values for TMAO levels compared to the first group.；
登录查看The exclusion criteria comprises; ST elevation myocardial infarction or stable or unstable coronary artery disease, heart failure, renal or hepatic disease, severe valvular disease, previous history of PCI or CABG, history stroke or bleeding within 3 months, peripheral arterial disease, pregnancy, chronic obstructive lung disease, acute and chronic infection, and history of cancer.；
登录查看中国医学科学院阜外医院深圳医院
518055
肝脏时间2025-03-29
医麦客2025-03-29
亚泰制药2025-03-29
深圳普瑞金生物药业股份有限公司2025-03-28
九洲药业2025-03-28
CDBIO成大生物2025-03-28
希格生科2025-03-28
新药前沿2025-03-28
君实医学2025-03-28
浙公网安备33011002015279
© pharnexcloud.com 2025 YAORONGYUN All Rights Reserved.
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
